Evolent Health faces heavy selling after cautious analyst call

Evolent Health shares fell over 5% pre-market, threatening an all-time low after KeyBanc downgraded the stock. The bank cited weak near-term EBITDA visibility and rising debt. Although Q4 revenue beat estimates, the company 2026 EBITDA forecast fell short of 2025 figures. Retail buzz increased significantly despite the negative guidance.